98%
921
2 minutes
20
Objectives: This study aimed to quantitatively reveal the difference between the descending aorta IDIF (IDIFa) and carotid artery IDIF (IDIFc) in the task of brain pharmacokinetic parametric analysis.
Methods: 18F-FDG dynamic PET data from 50 patients collected by UIH uEXPLORER PET/CT were used to extract the IDIFa and IDIFc; the Patlak graphical model (PGM) and irreversible 2-tissue compartmental model (2TCM) were applied for brain pharmacokinetic parametric analysis. The Patlak Ki and Vt images yielded by the two types of IDIFs are compared using relative error (RE), while the parameters K1∼k3 and fv were analyzed via paired t-tests to determine the significance of the differences.
Results: : IDIFa and IDIFc had significant differences in peak value (p = 0.0009) and curve integral value (p = 0.0012). Based on PGM, 0-15% REs were found between the Ki and Vt images yielded by IDIFa and IDIFc; based on 2TCM, significant differences were found in brainstem's K1 (p = 0.0009), left cerebellum's k3 (p = 0.0009) and all selected regions' fv and Ki (p < 0.05). Fitting residuals of IDIFa are lower than that of IDIFc without significant differences (p > 0.05).
Conclusions: : IDIFa and IDIFc have different curves characteristics and different brain pharmacokinetic parametric analysis results based on PGM and 2TCM. One should be prudential when using IDIFa to conduct brain dynamic PET parametric analysis.
Advances In Knowledge: This study quantitatively compares carotid artery and descending aorta IDIFs in the term of brain pharmacokinetic analysis, providing an important reference for nuclear clinicians.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/bjr/tqaf166 | DOI Listing |
Eur J Nucl Med Mol Imaging
September 2025
Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Purpose: Cardiac noradrenergic denervation visualized by meta-[I]iodobenzylguanidine ([I]MIBG) imaging supports the diagnosis of Parkinson's disease (PD). Recently, meta-[F] fluorobenzylguanidine ([F]MFBG) PET demonstrated favorable imaging characteristics compared with [I]MIBG scintigraphy for neuroendocrine tumors. We assessed [F]MFBG dosimetry and myocardial pharmacokinetics in healthy controls and PD patients.
View Article and Find Full Text PDFNaunyn Schmiedebergs Arch Pharmacol
September 2025
Pharmacology and Toxicology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Gamal Abdel Nasser, 11835, New Cairo, Egypt.
Licochalcone A (LCA), a natural flavonoid with potent anti-inflammatory properties, has shown promise as a neuroprotective agent. However, its ability to cross the blood-brain barrier (BBB) and exert central effects remains underexplored. In this study, we demonstrate for the first time that LCA enhances cognitive function in a lipopolysaccharide (LPS)-induced neuroinflammatory mouse model and effectively penetrates the BBB.
View Article and Find Full Text PDFJ Med Chem
September 2025
Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California San Diego, La Jolla, California 92093, United States.
Proteasome inhibitors are effective in treating hematologic cancers but have limited utility in brain tumors due to poor blood-brain barrier (BBB) penetration and metabolic instability. In this study, we developed novel macrocyclic peptide epoxyketone inhibitors with improved drug-like properties. Compounds were screened for cytotoxicity against brain cancer cell lines, permeability (PAMPA-BBB and Caco-2), and metabolic stability.
View Article and Find Full Text PDFCrit Rev Ther Drug Carrier Syst
September 2025
Department of Pharmacology, PSG College of Pharmacy, Coimbatore 641004, Tamil Nadu, India.
Treating neurological disorders is challenging due to the blood-brain barrier (BBB), which limits therapeutic agents, including proteins and peptides, from entering the central nervous system. Despite their potential, the BBB's selective permeability is a significant obstacle. This review explores recent advancements in protein therapeutics for BBB-targeted delivery and highlights computational tools.
View Article and Find Full Text PDFDrug Dev Res
September 2025
R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with "epidermal growth factor receptor (EGFR)" mutations playing a pivotal role in tumor progression and carcinogenesis. "Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)," such as Osimertinib, have significantly improved treatment outcomes by overcoming resistance mechanisms like the T790M mutation. However, Osimertinib's clinical application is limited by cardiotoxicity concerns, necessitating safer alternatives.
View Article and Find Full Text PDF